Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class
CD38×BCMA×CD3 Trispecific Antibody · ISB 2001 is currently in Phase 1 clinical trial in patients with...
Tag : Ichnos Glenmark Innovation
Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001
Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™...